DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
A Randomized，Multicenter, Open-Label，Phase II/III Study to Evaluate the Safety and Efficacy of Disitamab Vedotin Combined With Cadonilimab in Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Adenocarcinoma Who Have Progressed on r First-line Therapy
Sponsor: RemeGen Co., Ltd.
This PHASE2/PHASE3 trial investigates Gastric Cancer and Gastroesophageal Junction Adenocarcinoma and is currently actively recruiting participants. RemeGen Co., Ltd. leads this study, which shows 5 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2024 — May 2024 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- RemeGen Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Changsha, China , Chengdu, China , Harbin, China , Jinan, China , Kunming, China , Qingdao, China , Shanghai, China , Wuhan, China , Xiamen, China and 2 more locations